Menopause: The Journal of The North American Menopause Society最新文献

{"title":"Integrative medical group visits for menopause (MENOGAP): results of a pilot single-site feasibility study.","authors":"Lisa Taylor-Swanson, Wen Tu, Bob Wong, Xiaoming Sheng, Tammy Dunklebarger, Micaela Besser, Susan Smaellie, Hallie M Pedersen, Camille Moreno","doi":"10.1097/GME.0000000000002905","DOIUrl":"https://doi.org/10.1097/GME.0000000000002905","url":null,"abstract":"<p><strong>Objectives: </strong>Up to 82% of midlife women experience vasomotor and other symptoms during the menopausal transition and post menopause. Midlife women express interest in both conventional and integrative health approaches to symptom management. MENOGAP is an intervention with evidence-informed conventional and integrative health education content and acupuncture therapy delivered in a group medical visit, thus enabling clinicians to provide much-needed care to more women simultaneously. Women also learn self-care for stress management and wellness promotion. Limited research has been conducted on integrative group medical visits for women in perimenopause or postmenopause. This single-arm study was conducted in one site to ascertain the feasibility of recruiting and retaining participants, and the acceptability of study procedures, including data collection, and to assess participants' outcomes.</p><p><strong>Methods: </strong>MENOGAP was co-delivered by a menopause-certified physician and an acupuncturist. The primary outcome was level of feasibility, acceptability, and appropriateness, as measured by the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM). Secondary outcomes include changes in menopause-related symptoms, assessed with the Menopause Rating Scale (MRS), menopause self-efficacy, self-care behaviors, and menopause knowledge. Descriptive statistics were used for demographics and feasibility scales. Paired t tests and McNemar tests were used to assess changes between measures at baseline and post-intervention. Qualitative data were coded using thematic content analysis.</p><p><strong>Results: </strong>No enrolled participants withdrew and 90.4% attended three or more sessions. Participants reported high rates of acceptability, appropriateness, and feasibility. Statistically significant differences between pre-scores and post-scores were observed in MRS (P=0.005), somato-vegetative subscale (P=0.026), and psychological subscale (P=0.050), with overall MRS scores decreasing by 0.294 points and the somato-vegetative subscale by 0.300 points, suggesting modest but potentially clinically relevant improvement; knowledge of the menopausal transition increased by 1.727 points (95% CI: 0.729-2.725, P=0.002), and menopause self-efficacy increased by 0.612 points (95% CI: 0.139-1.085, P=0.013). Themes from the qualitative data included positive experiences and enjoyment, empowerment and emotional support, time constraints and travel challenges, useful information delivery and materials, environment and comfort concerns, and follow-up and communication needs.</p><p><strong>Conclusions: </strong>MENOGAP was found to be feasible, acceptable, and effective from the perspectives of the enrolled participants. Physical and psychological symptoms improved significantly after the 4-week visits compared with baseline, and participants' knowledge of menopaus","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond strength and balance: advancing fall risk assessment after menopause.","authors":"Xuezhi Daniel Jiang","doi":"10.1097/GME.0000000000002921","DOIUrl":"https://doi.org/10.1097/GME.0000000000002921","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the referral: building menopause competency in primary care.","authors":"Kimberly Ingelmo, Pallavi Khanna","doi":"10.1097/GME.0000000000002916","DOIUrl":"https://doi.org/10.1097/GME.0000000000002916","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Withania somnifera root extract on sleep quality, body composition, and menopausal symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial.","authors":"Simran Obhrai, Shweta Shenoy, Minaxi Arora","doi":"10.1097/GME.0000000000002894","DOIUrl":"https://doi.org/10.1097/GME.0000000000002894","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of Withania somnifera (ashwagandha) root extract supplementation on sleep quality, body composition, and menopausal symptoms in postmenopausal women.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled trial enrolled 66 postmenopausal women aged 45-65 years at a single center in Amritsar, India. Participants were randomly assigned to receive either ashwagandha root extract (600 mg/day; n=34) or placebo (n=32) for 12 weeks. Primary outcomes were sleep quality assessed by the Pittsburgh Sleep Quality Index, body composition assessed by dual-energy x-ray absorptiometry, and menopausal symptoms assessed by the Menopause Rating Scale. Secondary outcomes included health-related quality of life assessed by the 36-Item Short Form Health Survey. Bone mineral density was assessed as an exploratory outcome.</p><p><strong>Results: </strong>Sixty-three participants completed the study (ashwagandha n=33; placebo n=30). The ashwagandha group demonstrated significantly greater improvements in sleep quality (mean change -5.2 vs. -0.8; P<0.001), menopausal symptom scores (mean change -8.1 vs. -1.2; P<0.001), and body fat percentage (mean change -0.6% vs. +0.03%; P<0.01) compared with placebo. Quality of life improved significantly across multiple domains. No significant between-group differences in bone mineral density were observed. The intervention was well tolerated with no serious adverse events.</p><p><strong>Conclusions: </strong>Twelve weeks of ashwagandha supplementation significantly improved sleep quality, menopausal symptoms, and body composition in postmenopausal women, with an excellent safety profile.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148969549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonsedating neurotransmitter-modulating supplement for nonvasomotor sleep disturbance in menopause.","authors":"Stephen Carbonneau, Vincent Mysliwiec, Audra Lisa Doyle, Matthew Stratton, Alyssa Dweck, Jaime Tartar, Michaela Alesi, Laura Mason, James Komorowski, Trisha A VanDusseldorp","doi":"10.1097/GME.0000000000002880","DOIUrl":"https://doi.org/10.1097/GME.0000000000002880","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate a GABAergic, melatonergic, and glutamatergic supplement for enhancing sleep quality in perimenopausal and postmenopausal women with low vasomotor symptom (VMS) burden.</p><p><strong>Methods: </strong>A randomized, double-blind, placebo-controlled, decentralized trial (NCT07375095) was performed in healthy perimenopausal and postmenopausal women with moderate-to-severe sleep disturbance (patient-reported outcome measure information system sleep disturbance [PROMIS SD] SF 8b T-score ≥60) and minimal VMS (≤5 hot flashes and ≤2 night sweats/wk). Participants were randomized to a neurotransmitter-modulating supplement (NMS; L-theanine, gamma-aminobutyric acid, magnesium, S-adenosyl methionine, propyl gallate) or placebo for three weeks. Primary outcomes were changes in PROMIS SD and sleep-related impairment T-scores and responder rates. Secondary outcomes included diary-based total sleep time, sleep efficiency, and visual analog ratings of sleepiness and daytime functioning.</p><p><strong>Results: </strong>Of 128 randomized participants, 127 completed the trial (NMS, n = 65; placebo, n = 62). Baseline characteristics and VMS frequency were similar between groups (3.0 ± 4.0 hot flashes and 1.9 ± 1.7 night sweats/wk). At week 3, NMS significantly improved PROMIS SD T-score (LS mean difference: -11.1 [95% CI, -13.6 to -8.6]; P = 0.0012) and responder rate (90.9% vs. 45.2%; P < 0.001) versus placebo. PROMIS sleep-related impairment T-score (-4.8 [95% CI, -7.3 to -2.3]; P < 0.001) and responder rate (50.8% vs. 32.2%; P = 0.047) also improved. All primary endpoints reached significance by week 2. NMS increased total sleep time by 40.9 minutes versus a 14.9-minute decrease with placebo (P < 0.001), and sleep efficiency improved by 7.4% versus 3.4% (P = 0.021). No between-group differences in adverse events were observed.</p><p><strong>Conclusion: </strong>In perimenopausal and postmenopausal women with disrupted sleep but minimal VMS, a NMS significantly improved sleep quality and duration.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148969570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the effects of two sexual counseling models, GES (Good Enough Sex) and PLISSIT (Permission, Limited Information, Specific Suggestions, Intensive Therapy), on sexual dysfunction in postmenopausal women: a randomized controlled trial.","authors":"Leila AliAghdami, Fatemeh Nasiri-Amiri, Hossein-Ali Nikbakht, Farideh Mohsenzadeh-Ledari, Samira Barjasteh, Mah Monir Haghighi","doi":"10.1097/GME.0000000000002882","DOIUrl":"https://doi.org/10.1097/GME.0000000000002882","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate and compare the impacts of GES (Good Enough Sex) and PLISSIT (Permission, Limited Information, Specific Suggestions, Intensive Therapy) sexual counseling models on sexual intimacy, sexual quality of life, and sexual satisfaction relative to standard care.</p><p><strong>Methods: </strong>This randomized controlled trial included 108 postmenopausal women aged 45-60 years, recruited from comprehensive health centers in Urmia, Iran, between June 2023 and December 2024. Participants were randomly assigned to three groups of 36 individuals each: the GES, PLISSIT, and control groups. Data were collected using validated questionnaires that assessed sexual intimacy, sexual quality of life, and sexual satisfaction at baseline and 2 months postintervention. The GES group participated in weekly group counseling sessions, while the PLISSIT group received individual counseling over a 4-week period. The control group received standard care without any specialized counseling interventions. Sample characteristics were summarized using descriptive statistics (means and SDs). Inferential tests (χ2, Fisher exact, paired t tests, ANOVA, Kruskal-Wallis, and Tukey) were used for group comparisons and change analysis, with P < 0.05 considered significant.</p><p><strong>Results: </strong>Both the GES and PLISSIT groups demonstrated significant improvements in sexual intimacy, sexual quality of life, and sexual satisfaction, compared with the control group (P < 0.001). The intervention demonstrated a substantial improvement compared with the control group. The standardized mean difference (SMD) for overall outcomes was 1.83 (95% CI: 1.27-2.38). Within-group analysis showed a large positive effect in the PLISSIT group (SMD = 1.48; 95% CI: 0.98-1.97) and the GES group (SMD = 1.83; 95% CI: 1.27-2.38), whereas the control group showed no meaningful change (SMD = -0.26; 95% CI: -0.60 to 0.08).</p><p><strong>Conclusions: </strong>Both the GES and PLISSIT models effectively enhance sexual intimacy, sexual quality of life, and sexual satisfaction in postmenopausal women. Incorporating structured sexual counseling into health care strategies can significantly improve their quality of life, emphasizing the importance of tailored, accessible interventions.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148969948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of enhanced protein intake with handgrip strength in postmenopausal women: a systematic review and meta-analysis.","authors":"Faustino R Pérez-López, Ana M Fernández-Alonso, Helena Losa-Puig, Pascual García-Alfaro","doi":"10.1097/GME.0000000000002870","DOIUrl":"https://doi.org/10.1097/GME.0000000000002870","url":null,"abstract":"<p><strong>Importance: </strong>Low handgrip strength (HGS) is a highly prevalent condition in postmenopausal women, although there is no clear evidence about the convenience and benefit of enhanced protein intake (EPI).</p><p><strong>Objective: </strong>This systematic review and meta-analysis evaluate the association between EPI and HGS in postmenopausal women.</p><p><strong>Evidence review: </strong>The meta-analysis protocol was registered in the PROSPERO database (CRD420261299335). We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was conducted up to February 2026 across four databases (PubMed, Web of Science, Scopus, and LILACS) for studies comparing the effect of EPI with mild protein intake on the HGS in postmenopausal women. The quality of the included studies was assessed using the Newcastle-Ottawa Scale. Statistical analyses were performed with the RevMan 5.4 software. Results are reported as standardized mean difference (SMD) and the 95% CI.</p><p><strong>Findings: </strong>Seven studies with low or moderate risk of bias, including 8,922 postmenopausal women, showed that EPI was significantly associated with HGS (SMD: 0.15, 95% CI: 0.10 to 0.20; Z = 5.54, P < 0.0001; I2 = 6%, τ2 = 0.00) compared with the control group under low protein intake. There was a lower body mass index in women under EPI compared with the control group (SMD: -0.43, 95% CI: -0.68 to -0.18; Z = 3.35, P < 0.0001; I2 = 90%, τ2 = 0.04), and there was no significant age difference (SMD: -0.17, 95% CI: -0.36 to 0.02; I2 = 83%, τ2 = 0.08). The HGS sensitivity analysis for protein intake and HGS indicates that the statistical heterogeneity was low, ranging I2 from 0% to 22%.</p><p><strong>Conclusion and relevance: </strong>Postmenopausal women with EPI have significantly higher HGS and lower body mass index compared with those with lower protein intakes.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting bilateral salpingo-ooophorectomy at the time of hysterectomy.","authors":"Toni Horton","doi":"10.1097/GME.0000000000002918","DOIUrl":"https://doi.org/10.1097/GME.0000000000002918","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenging perception of inevitable health decline at menopause: empowering women and combatting misinformation.","authors":"Zachary Nash, Martha Hickey","doi":"10.1097/GME.0000000000002917","DOIUrl":"https://doi.org/10.1097/GME.0000000000002917","url":null,"abstract":"","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of hormone therapy on mood in a real-world clinical setting: a retrospective observational study.","authors":"Samantha Fairweather, Laurie Jeffers, Dana R Gossett, Emily Friedman, Alberta Twi-Yeboah, Samantha Dunham","doi":"10.1097/GME.0000000000002873","DOIUrl":"https://doi.org/10.1097/GME.0000000000002873","url":null,"abstract":"<p><strong>Objective: </strong>Mood disturbances-including depressed mood, irritability, anxiety, and mental exhaustion-are common during the menopause transition, affecting up to 68% of women. While menopausal hormone therapy (HT) is FDA-approved for vasomotor and genitourinary symptoms, its role in managing mood symptoms remains less well understood. This retrospective, comparative study evaluated the impact of systemic HT on mood in a cohort of HT-naive individuals.</p><p><strong>Methods: </strong>We included 260 patients presenting to an urban, academic menopause center between 2023 and 2025 who completed the Menopause Rating Scale (MRS) before and after initiating systemic HT for FDA-approved indications. MRS psychological subdomain scores covering depressive mood, irritability, anxiety, and mental exhaustion were analyzed. Most patients (96.5%) received transdermal estradiol, had an average age of 52.1 years, and a mean follow-up of 4.5 months. Notably, 51% had a history of anxiety or depression, and 24% were on antidepressant therapy at baseline.</p><p><strong>Results: </strong>Results showed a significant reduction in MRS psychological subdomain scores from baseline to follow-up (P<0.001). The proportion of patients with severe mood symptoms (score ≥7) decreased from 62.3% to 24.6%. Improvement was greatest in those with severe baseline symptoms (mean change: -3.85, SE: 0.223). Treatment response did not differ by psychiatric history, age, menopausal stage, or antidepressant use.</p><p><strong>Conclusions: </strong>These findings suggest systemic HT may improve mood symptoms in midlife, especially among those with elevated baseline severity, independent of prior mental health diagnosis, antidepressant use, or menopause stage. These findings support further investigation of HT's impact on mood in midlife women.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}